Skip to main content

Population Diagnostics, Empire Genomics Sign Co-Marketing Pact

NEW YORK (GenomeWeb News) - Population Diagnostics and Empire Genomics have signed a co-marketing agreement with the goal of developing molecular diagnostic tests, Population Diagnostics said today.
 
Under the terms of the “multifaceted” deal, EG of Buffalo, NY, will have access to PDI’s core technology platform for discovering copy number polymorphisms. EG will use PDI’s technology to support its internal and collaborative projects, as well as in service and supply relationships with third parties.
 
Melville, NY-based PDI, meanwhile, will use data from EG's array-based comparative genomics platform to build its own technology platform as well as its DNA biomarker discovery program.
 
The companies have also agreed to co-market and co-promote each other’s products and services.
 
PDI has built a working prototype of its platform, which the company claims has helped identify medically relevant biomarkers for autism.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.